ClinicalTrials.gg
RecruitingNCT07794410TRANSIT CDUpdated Aug 31, 2026

A Study Comparing Transperineal Ultrasound, Magnetic Resonance Imaging, Endoscopic Ultrasound, and Examination Under Anesthesia to Detect and Classify Perianal Fistulas in Patients With Crohn's Disease or Fistulas of Unknown Cause

An interventional study of Transperineal Ultrasound (TPUS) and Magnetic Resonance Imaging (MRI) in Crohn Disease (CD) and Cryptoglandular Perianal Fistula, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 1 site in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Asian Institute of Gastroenterology, India · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this study is to learn how well different imaging tests detect and describe perianal fistulas in adults with Crohn's disease or fistulas with no known cause (cryptogenic). Perianal fistulas are painful tunnels that form near the anus and can lead to discharge, swelling, or infection. The main questions this study aims to answer are:

How accurate is transperineal ultrasound (TPUS) compared to magnetic resonance imaging (MRI) in finding fistulas? How well do these tests identify key features like internal openings and abscesses? Do the test results help doctors make better treatment decisions?

Researchers will compare TPUS and MRI to two other imaging methods:

Endoscopic ultrasound (EUS), which uses a small camera and ultrasound inside the rectum Examination under anesthesia (EUA), in which a surgeon checks the area while the participant is asleep

All participants will:

Be adults between the ages of 18 and 75 Have a suspected or confirmed perianal fistula Be able to complete all four tests-TPUS, MRI, EUS, and EUA-within 10 days Participants will not receive any experimental treatments. The tests are part of routine care and will be done using advanced equipment by expert doctors. Each test result will be used to compare how accurate and useful the test is in real-life diagnosis and treatment planning.

This study may help make fistula diagnosis faster, safer, and more affordable-especially in settings where access to MRI or surgery is limited. It may also support the use of TPUS as a first step in evaluating perianal fistulas in people with Crohn's disease.

Read the detailed description

Perianal fistulas are a challenging and often debilitating complication of anorectal and inflammatory bowel diseases, particularly Crohn's disease. Up to 40% of people with Crohn's disease may develop perianal fistulas during the course of their illness. These fistulas are frequently complex, may recur, and can severely affect quality of life. They are associated with symptoms such as discharge, swelling, pain, infection, and, in some cases, incontinence or systemic sepsis. Accurate diagnosis and anatomical characterization of these fistulas are essential for determining the most effective medical and surgical treatment strategies.

Traditional imaging strategies include Magnetic Resonance Imaging (MRI), which is currently considered the non-invasive standard for anatomical delineation, and Examination Under Anesthesia (EUA), which serves as the gold standard due to the ability to directly examine the anatomy and intervene surgically if necessary. However, both methods have limitations. MRI is costly, may not be readily available in resource-limited settings, and is not suitable for all patients (e.g., those with certain implants or claustrophobia). EUA is invasive, requires anesthesia, and may not be feasible for repeated use in follow-up or outpatient care.

Alternative imaging modalities such as Transperineal Ultrasound (TPUS) and Endoscopic Ultrasound (EUS) are being explored for their diagnostic utility. TPUS is a non-invasive, low-cost, real-time modality that can be performed at the bedside or in outpatient settings. EUS, while more invasive, offers high-resolution images of the anal canal and surrounding structures and is increasingly used for evaluating anorectal diseases.

The TRANSIT-CD study (A Quadrimodal Comparison of TRAnsperiNeal and MR-based Sonographic Investigation with Integrated Testing using Endoscopic Ultrasound and Examination Under Anesthesia) is a prospective, single-center, diagnostic accuracy study designed to compare the performance of four imaging modalities-TPUS, MRI, EUS, and EUA-in evaluating perianal fistulas in people with Crohn's disease and cryptogenic (non-Crohn's) fistulas.

Study Design and Objectives The study will enroll adults aged 18 to 75 years with a clinical diagnosis or suspicion of perianal fistula. Each participant will undergo four imaging tests-TPUS, MRI, EUS, and EUA-within a maximum interval of 10 days. The order of testing is predefined and all interpretations will be performed independently by blinded experts in each modality.

The primary objective is to compare the per-lesion sensitivity of TPUS and MRI for detecting perianal fistulas, using EUS as the reference standard and EUA as the gold standard.

Secondary objectives include:

Comparing TPUS and MRI for detecting internal openings and perianal abscesses Evaluating classification accuracy using Parks classification and American Gastroenterological Association (AGA) criteria (simple vs. complex fistulas) Determining whether findings from TPUS and MRI result in a change in clinical management

Exploratory objectives include:

Assessing diagnostic accuracy by disease type (Crohn's vs. cryptogenic) Comparing modality performance in high (above the levator ani muscle) vs. low fistulas Evaluating inter-modality agreement and confidence levels of reporting physicians Methodology

Transperineal Ultrasound (TPUS) Performed by an expert radiologist using a high-end ultrasound platform with microconvex and high-frequency linear probes. The patient is positioned in the left lateral decubitus position. Both axial and sagittal images are obtained. Parameters assessed include tract presence, type, internal openings, secondary extensions, and associated abscesses.

Magnetic Resonance Imaging (MRI) Conducted using a 1.5 Tesla MRI scanner with T2-weighted, STIR, and post-contrast T1-weighted fat-suppressed sequences in axial, sagittal, and coronal planes. MRI findings are independently interpreted by radiologists blinded to TPUS and EUS findings. Fistulas are characterized using standard classification systems and the presence of abscesses and internal openings is documented.

Endoscopic Ultrasound (EUS) EUS is performed using a linear echoendoscope and dedicated EUS processor. The procedure does not require bowel preparation. A 360-degree evaluation of the anal canal and surrounding structures is performed to detect fistulous tracts, internal openings, and collections. EUS serves as the reference standard for diagnostic comparison.

Examination Under Anesthesia (EUA) EUA is performed by an experienced colorectal surgeon under spinal or general anesthesia. This procedure allows direct probing of the fistula tract, identification of internal openings, and classification of the fistula using tactile and visual assessment. EUA is considered the gold standard in this study.

Each modality's findings are documented in structured case report forms. The findings include:

Fistula presence and number Parks classification and AGA complexity score Internal and external openings Abscess presence and dimensions Secondary tracts Confidence scores All data are recorded per lesion, per patient.

Blinding and Data Integrity All imaging studies will be interpreted independently by modality-specific experts, who are blinded to the findings of other modalities. Discrepant findings will be resolved through consensus by the principal investigators. A secure electronic database will be used for data capture, ensuring patient confidentiality and auditability.

Clinical Impact Assessment The study will also track whether imaging findings lead to a change in management plans (e.g., additional imaging, medical therapy, surgical planning). These decisions will be documented by treating clinicians based on the initial and subsequent imaging findings.

Sample Size and Statistical Analysis

This pilot study aims to recruit approximately 100 participants. Based on previous literature (Maconi et al., 2017), the study is powered to detect a difference in diagnostic sensitivity between TPUS and MRI. The analysis includes:

Calculation of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) McNemar's test for paired comparisons Cohen's kappa for inter-modality agreement Receiver Operating Characteristic (ROC) curve analysis Subgroup analyses by diagnosis type and fistula location

Significance This is the first prospective study to compare all four major imaging modalities in the same patient cohort with suspected or confirmed perianal fistulas. By benchmarking TPUS and MRI against both EUS and EUA, the TRANSIT-CD study provides a robust framework for evaluating diagnostic accuracy and impact on care. The results may support broader use of TPUS as a first-line diagnostic tool, particularly in outpatient and low-resource settings where access to MRI or EUA is limited. It may also help refine imaging protocols for complex perianal Crohn's disease.

Ethical Considerations All imaging procedures in this study are part of routine clinical care. No experimental treatments are being tested. The study has been approved by the Institutional Ethics Committee and informed consent will be obtained from all participants. There are no additional risks introduced beyond standard diagnostic procedures. All data will be anonymized and securely stored.

02

Conditions studied

  • Crohn Disease (CD)
  • Cryptoglandular Perianal Fistula

Keywords

  • fistula
  • crohn disease
  • transperineal ultrasound
  • magnetic resonance imaging
  • endoscopic ultrasound
  • examination under anaesthesia
03

In context

Crohn Disease

1,992 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

This study's planned enrollment of 50 is below the median of 67 across 1,260 interventional studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

Asian Institute of Gastroenterology, India is the lead sponsor of 135 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between 18 and 75 years of age
  • Clinical suspicion or diagnosis of perianal fistula
  • Fistula etiology can be Crohn's disease or cryptogenic/tubercular (non-Crohn's)
  • Ability to undergo all four imaging procedures (TPUS, MRI, EUS, and EUA) within a 10-day period
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Known or suspected anorectal
  • Pregnancy or breastfeeding
  • to any of the imaging procedures:
  • MRI (e.g., presence of metal implants or claustrophobia)
  • EUS (e.g., severe anal stenosis or intolerance to procedure)
  • Anesthesia required for EUA (e.g., significant cardiopulmonary disease)
  • Prior surgery or seton placement at the index fistula site
  • Incomplete or failed imaging in any one of the modalities
  • Inability to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Single Group: Quadrimodal Imaging Assessment

    All participants in this arm will undergo four diagnostic imaging procedures-transperineal ultrasound (TPUS), magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), and examination under anesthesia (EUA)-in a predefined sequence. Each imaging modality will be used to evaluate the presence, type, and extent of perianal fistulas. This single-arm design allows within-subject comparison of diagnostic accuracy and clinical impact across modalities.

    Diagnostic Test: Transperineal Ultrasound (TPUS) · Diagnostic Test: Magnetic Resonance Imaging (MRI) · Diagnostic Test: Endoscopic Ultrasound (EUS) · Diagnostic Test: Examination Under Anesthesia (EUA)

Interventions

  • Diagnostic testTransperineal Ultrasound (TPUS)

    Participants will undergo TPUS using a high-frequency linear and microconvex probe to evaluate fistula tracts, internal openings, and abscesses.

  • Diagnostic testMagnetic Resonance Imaging (MRI)

    MRI of the pelvis will be performed using standardized T2-weighted, STIR, and post-contrast sequences for anatomical characterization of fistulas.

  • Diagnostic testEndoscopic Ultrasound (EUS)

    EUS of the anorectal canal will be performed using a linear echoendoscope to visualize internal openings, fistula tracts, and perirectal collections. EUS serves as the reference standard.

  • Diagnostic testExamination Under Anesthesia (EUA)

    Participants will undergo EUA by a colorectal surgeon to probe fistula tracts and identify internal openings. EUA serves as the gold standard comparator.

06

What researchers measure

Primary outcomes

  1. Per-lesion sensitivity of transperineal ultrasound (TPUS) and magnetic resonance imaging (MRI) for detecting perianal fistulas

    To determine and compare the diagnostic sensitivity of TPUS and MRI for identifying individual fistulous tracts, using endoscopic ultrasound (EUS) as the reference standard and examination under anesthesia (EUA) as the gold standard.

    Time frame: Within 10 days of enrollment (all four imaging modalities completed within this window)

Secondary outcomes

  1. Sensitivity of TPUS vs MRI for detecting internal openings

    Compare how well TPUS and MRI detect internal openings of perianal fistulas, using EUS and EUA as benchmarks.

    Time frame: Within 10 days of enrollment

  2. Classification accuracy (Parks criteria) of transperineal ultrasound (TPUS) versus magnetic resonance imaging (MRI)

    Compare the ability of TPUS and MRI to correctly classify fistulas using the Parks classification system, compared to examination under anaesthesia (EUA).

    Time frame: Within 10 days of enrollment

  3. Sensitivity of transperineal ultrasound (TPUS) vs magnetic resonance imaging (MRI) for detecting perianal abscesses

    Evaluate the ability of TPUS and MRI to detect perianal abscesses compared with endoscopic ultrasound (EUS) and examinaion under anaesthesia (EUA).

    Time frame: Within 10 days of enrollment

  4. Impact on clinical management based on imaging modality

    Proportion of participants whose treatment plan was changed after magnetic resonance imaging (MRI) vs after transperineal ultrasound (TPUS).

    Time frame: Up to 14 days after imaging

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared publicly due to the nature of the diagnostic imaging data, which includes potentially identifiable health information. Data will be stored securely and used only by the study team for the purpose of predefined analyses. Any future data sharing will require additional ethical approval and participant consent.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 20 months after the start.

Of 287 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 20 months is below that.

Counting every sponsor, half of 299 studies reached it within 45 months; a quarter within 21 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2025
First posted
Aug 31, 2026
StartActual
Jul 25, 2025
Primary completionEst.
Apr 15, 2027
CompletionEst.
Apr 30, 2027
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07794410
Responsible party
Sponsor
First posted
Aug 31, 2026
Start date
Jul 25, 2025
Primary completion
Apr 15, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Aug 31, 2026

Study contacts

Partha Pal, MD, DNB, MRCP (UK), FASGE
Contact
partha0123456789@gmail.com
+918945906823

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion